Episode Details
Back to Episodes
May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI
Description
Pfizer's 25-valent pneumococcal shot shows 8.8x–15x higher antibody levels vs. Prevnar 20 in Phase 2, advancing to Phase 3. BMS deploys Claude across 30,000+ employees in landmark pharma-AI deal. Lilly acquires Engage Bio for $202M. Tavneos linked to 20 deaths in Japan.
Visit us at www.thepharmacloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Prevnar 20, 25vPnC, pneumococcal vaccine, Bristol Myers Squibb, BMS, Anthropic, Claude, artificial intelligence, enterprise AI, Eli Lilly, Engage Biologics, Gilead Sciences, Yuhan, Amgen, Tavneos, avacopan, ImmunityBio, Anktiva, NMIBC, Parabilis, Relay Therapeutics, GHO Capital, CBC Group, PDUFA, Lilly, Novartis, Roche, Merck, Gilead, Regeneron